Skip to main content

Table 2 Number of rifampicin-associated adverse reactions reported to Uppsala Monitoring Centre (UMC), the Collaboration Centre of the WHO Programme for International Drug Monitoring

From: Hypersensitivity reaction with multi-organ failure following re-exposure to rifampicin: case report and review of the literature including WHO spontaneous safety reports

  Number of rifampicin-associated adverse reactions in VigiBase (% of total reports) worldwide Number of rifampicin-associated adverse reactions in VigiBase (% of total reports) in Switzerland
Total rifampicin-associated reports 37,812 192
Drug reactions with eosinophilia and systemic symptoms (PT) 305 (0.8) 9 (5)
Events of hepatic disorders reported with terms of Immune system disorder (SOC) n.d.* n.d.*
 Hepatitis (PT) 74 (0.2) 3 (2)
 Jaundice (PT) 26 (0.1)
 Acute hepatic failure (PT) 12 (< 0.1) 2 (1)
 Hepatic function abnormal (PT) 25 (0.1)
 Hepatic enzymes increase (incl. ALT, transaminases) (PT) 52 (0.1) 3 (2)
 Other hepatic terms reported Not done 4 (2)
Lower respiratory tract inflammatory and immunological conditions (HLGT) 35 (0.1) 2 (1)
Pneumonitis (PT) 9 (< 0.1)
Hemolytic anemia, hemolysis, autoimmune hemolytic anemia (PT)** 187 (0.5) 2 (1)
Tubulointerstitial nephritis, nephritis, allergic nephritis (PT)*** 160 (0.4) 6 (3)
  1. * n.d.: in one report, one or more than one PTs may have been reported, therefore the sum is not applicable; ** most cases for haemolytic anaemia; *** most cases for tubulointerstitial nephritis